Join the club for FREE to access the whole archive and other member benefits.

Gyroscope secures $148M to develop treatment for rare eye diseases

29-Mar-2021

Key points from article :

Gyroscope Therapeutics Limited, which focuses on treating diseases of the eye, raised $148.0 million in a Series C financing.

To advance the clinical development of GT005, company’s lead investigational gene therapy.

Gene therapy to evaluate the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

GT005 received Fast Track designation from the FDA and is being evaluated in Phase II clinical trials.

Funds to further advance its early stage pipeline and innovative delivery technology.

“Excited to welcome leading life sciences investors on our journey to deliver gene therapy beyond rare disease,” - Khurem Farooq, Chief Executive Officer at Gyroscope.

"Gyroscope is well positioned to develop novel treatments for the millions of people with serious eye diseases," - Wouter Joustra, General Partner at Forbion.

Treatment for age-related macular degeneration can slow progression to extend vision for as long as possible.

Funds to advance gene therapy for age-related macular degeneration & innovative delivery system

Mentioned in this article:

Company

London-based company developing gene therapies and delivery technologies for eye diseases

Company Representative

Chief Executive Officer at Gyroscope

Company Representative

General partner at Forbion and Board member at Gyroscope Therapeutics